Dallas-based MedCognetics and its academic R&D partners will have $750,000 more to spend refining diversity-calibrated AI for early detection of breast cancer, thanks to the NIH’s “AIM-AHEAD” initiative.

The medications included in the program treat more than 80 conditions.

The executive branch of the European Union has launched a major project to aggregate cancer imaging data from across the continent so it can be readily tapped by healthcare providers, medical schools and industry innovators.

Would residency directors do better to favor high-achieving students from schools of more modest national status?

The American College of Radiology has worked out a way to protect patients from surprise medical bills for out-of-network services while modifying third-party arbitration so it sensibly serves providers and payers alike.  

Johnson & Johnson has discontinued its Mosaico clinical trial that aimed to protect against HIV after its Phase 3 study revealed the regiment was safe but ineffective.

Promaxo Inc. of Oakland, Calif., sold eight of its systems for performing AI-equipped, MRI-guided prostate interventions in the fourth quarter of 2022. The company launched a year prior and has now topped $15 million in sales.  

The partnership is with ScImage, a California-based healthcare technology company known for its extensive EI background.